ArticleiScience2026
From byproduct to biotherapeutic: Comparative study of buffy coats and leukoreduction system chambers for NK cell-based immunotherapies.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cell immunotherapies require reliable access to large numbers of functionally consistent cells, yet obtaining sufficient material remains challenging. Therefore, we evaluated leukoreduction system chambers (LRSCs), routinely discarded after plateletpheresis, as a low-cost and logistically accessible addition to buffy coats (BCs) for NK cell isolation. Although LRSCs contain less volume than BCs, they provide higher concentrations of mononuclear cells and NK cells. The total NK yield per unit is lower, but viability and cytotoxic function are comparable to BCs. LRSC-derived NK cells display increased NKp46 and NKG2A expression with a higher proportion of CD56
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.